Debbie van Baarle Selected Research

HLA-B57 antigen

1/2022	Protective HLA Alleles Recruit Biased and Largely Similar Antigen-Specific T Cell Repertoires across Different Outcomes in HIV Infection.
11/2014	Differential characteristics of cytotoxic T lymphocytes restricted by the protective HLA alleles B27 and B57 in HIV-1 infection.
3/2008	A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef.
1/2008	An unanticipated lack of consensus cytotoxic T lymphocyte epitopes in HIV-1 databases: the contribution of prediction programs.
9/2007	Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection.
1/2005	High responsiveness of HLA-B57-restricted Gag-specific CD8+ T cells in vitro may contribute to the protective effect of HLA-B57 in HIV-infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Debbie van Baarle Research Topics

Disease

28	Infections 12/2021 - 02/2004
16	HIV Infections (HIV Infection) 01/2022 - 06/2004
8	Disease Progression 01/2022 - 02/2006
8	Tuberculosis (Tuberculoses) 01/2019 - 07/2005
7	COVID-19 10/2022 - 01/2021
5	Acquired Immunodeficiency Syndrome (AIDS) 11/2014 - 11/2005
3	Chronic Renal Insufficiency 07/2022 - 01/2021
3	Virus Diseases (Viral Diseases) 01/2015 - 09/2005
3	Coinfection 01/2013 - 07/2005
2	Mumps 12/2021 - 01/2018
2	Neoplasms (Cancer) 12/2021 - 08/2005
2	Persistent Infection 11/2020 - 01/2014
2	Measles 01/2019 - 01/2018
2	Hepatitis C 01/2015 - 01/2011
2	Viremia 01/2013 - 07/2008
2	Communicable Diseases (Infectious Diseases) 01/2013 - 02/2009
2	Chronic Hepatitis C 12/2011 - 09/2010
2	Bronchiolitis Obliterans Syndrome 09/2011 - 06/2009
2	Epstein-Barr Virus Infections 04/2006 - 08/2005
1	Atherosclerosis 01/2020
1	Pneumococcal Infections 01/2020
1	Cytomegalovirus Infections (Inclusion Disease) 01/2018
1	Chickenpox 01/2018
1	Human Influenza (Influenza) 01/2018
1	Rubella (German Measles) 01/2018
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2016
1	Body Weight (Weight, Body) 01/2016
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2013
1	Pulmonary Tuberculosis 12/2012
1	Hematologic Diseases (Blood Diseases) 06/2009
1	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2008
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 05/2006
1	Asymptomatic Infections 11/2005
1	Lymphopenia (Lymphocytopenia) 11/2005
1	Visceral Leishmaniasis (Kala Azar) 11/2005
1	Lymphoma (Lymphomas) 08/2005

Drug/Important Bio-Agent (IBA)

12	EpitopesIBA 01/2022 - 02/2004
9	AntigensIBA 01/2022 - 08/2005
7	VaccinesIBA 10/2022 - 01/2014
6	HLA-B57 antigenIBA 01/2022 - 01/2005
5	HLA-B Antigens (HLA-B)IBA 01/2022 - 02/2009
5	CytokinesIBA 01/2021 - 11/2005
4	2019-nCoV Vaccine mRNA-1273IBA 07/2022 - 01/2021
4	HLA Antigens (Human Leukocyte Antigens)IBA 01/2016 - 09/2005
4	Peptides (Polypeptides)IBA 01/2015 - 01/2011
3	COVID-19 VaccinesIBA 12/2021 - 01/2021
3	Biomarkers (Surrogate Marker)IBA 01/2019 - 01/2016
3	Tuberculin (PPD)IBA 01/2019 - 07/2006
3	Interleukin-2 (IL2)IBA 01/2016 - 02/2006
3	Proteins (Proteins, Gene)FDA Link 01/2015 - 09/2005
3	Antiviral Agents (Antivirals)IBA 01/2014 - 08/2005
3	DNA (Deoxyribonucleic Acid)IBA 01/2008 - 08/2005
2	Ad26COVS1IBA 10/2022 - 01/2021
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2021
2	Immunoglobulin G (IgG)IBA 12/2021 - 01/2018
2	Biological ProductsIBA 03/2016 - 02/2006
2	ChemokinesIBA 01/2016 - 07/2005
2	HLA-DR Antigens (HLA-DR)IBA 01/2013 - 07/2005
2	Ribavirin (Virazole)FDA LinkGeneric 12/2011 - 09/2010
2	Rituximab (Mabthera)FDA Link 09/2011 - 06/2009
1	Everolimus FDA Link 01/2022
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2022
1	HLA-A2 Antigen (HLA A2 Antigen)IBA 12/2021
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021
1	Apolipoproteins E (ApoE)IBA 01/2020
1	Neutralizing AntibodiesIBA 01/2019
1	AntibodiesIBA 01/2019
1	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2018
1	Immunologic Factors (Immunomodulators)IBA 01/2016
1	Vitamin D FDA LinkGeneric 01/2016
1	Interleukin-17 (Interleukin 17)IBA 01/2016
1	HLA-A Antigens (HLA-A)IBA 11/2014
1	Granzymes (Granzyme)IBA 01/2014
1	Mycobacterium tuberculosis antigensIBA 12/2012
1	SteroidsIBA 09/2011
1	InterferonsIBA 01/2011
1	Monoclonal AntibodiesIBA 05/2010
1	ProteomeIBA 01/2010
1	AIDS VaccinesIBA 07/2008
1	HLA-B27 Antigen (HLA B27 Antigen)IBA 01/2008
1	Isoniazid (Ftivazide)FDA LinkGeneric 07/2006
1	Interleukin-4 (Interleukin 4)IBA 11/2005
1	Interferon-gamma (Interferon, gamma)IBA 11/2005
1	leishmaninIBA 11/2005
1	IonomycinIBA 11/2005
1	Epstein-Barr Virus Nuclear AntigensIBA 11/2005
1	HLA-DR3 Antigen (HLA DR3 Antigen)IBA 09/2005
1	Chemokine ReceptorsIBA 07/2005
1	Chemokine CCL4IBA 07/2005
1	Macrophage Inflammatory Proteins (Macrophage Inflammatory Protein 1)IBA 07/2005

Therapy/Procedure

10	Highly Active Antiretroviral Therapy (HAART) 10/2018 - 03/2005
6	Therapeutics 01/2016 - 07/2005
3	Stem Cell Transplantation 09/2011 - 12/2008
2	Transplantation 01/2022 - 06/2008
2	Ligation 01/2019 - 10/2018
1	Immunotherapy 12/2021
1	Hematopoietic Stem Cell Transplantation 12/2021
1	Drug Therapy (Chemotherapy) 12/2021
1	Resuscitation 12/2012
1	Kidney Transplantation 04/2006